Wednesday, July 6, 2016

"This growth [of 11.5% from 2014 to 2015 in the cost of cancer drugs and supportive therapies] ...

... was very much fueled by a sustained level of innovation. There are now 20 tumor types treated by one or more of 70 therapies that have launched in the last five years.... Everyone is wrestling with this surge of innovation, [which IMS] expects to continue at least through 2020."

— Murray Aitken, IMS Health senior VP and executive director of the IMS Institute for Healthcare Informatics, during a recent conference call to discuss his institute's new report, Global Oncology Trend Report: A Review of 2015 and Outlook to 2020.

No comments:

Post a Comment